Development Commercialization. Subject to the terms and conditions of this Agreement from and after such time as Amgen exercises the Option, Amgen shall have the right to control, and as between the Parties shall be solely responsible (subject to the Co-Funding Arrangement) for the costs associated with, the Development, commercialization, manufacturing, distribution, marketing, promotion and other exploitation of Compounds and Products in the Field in the Territory. Without limiting the generality of the foregoing, except as expressly set forth in Section 3.7, Amgen shall be responsible for the worldwide supply of all Compound and Products necessary for the foregoing activities.
Development Commercialization. Company wishes to evaluate the Technology with a view to potentially developing it into a commercial product. University acknowledges that Company has many opportunities to evaluate technologies (both on its own and in connection with others) and in many cases decides to not develop, to discontinue development, to not commercialize, or to discontinue commercialization of a product incorporating particular intellectual property rights. AS A RESULT, UNIVERSITY ACKNOWLEDGES AND AGREES THAT COMPANY HAS NO OBLIGATION TO DEVELOP OR COMMERCIALIZE A PRODUCT THAT INCORPORATES ANY LICENSED RIGHTS DURING THE TERM OF THE OPTION.
Development Commercialization. 3.1 The Parties acknowledge that, as at the Effective Date, Licensee has provided Inserm Transfert with a development plan (the “Development Plan”) which describes the terms under which Licensee intends to conduct the Development Activities, the estimated schedule for performance of said Development Activities as well as the anticipated date of first commercial sale of the Products. The Development Plan is attached as Exhibit A, shall form an integral part of the Agreement and may be updated by mutual agreement between the Parties. For clarification, Inserm Transfert shall not refuse the updated Development Plan without reasonable justification. Licensee shall use commercially reasonable efforts to conduct and complete in a timely manner the development as agreed in the Development Plan.
3.2 Licensee undertakes to inform Inserm Transfert of any unforeseen event relating to said Development Activities. To this end, Licensee shall provide Inserm Transfert, within sixty (60) days from the 31st of December of each calendar year, with an annual written report describing the progress of the development of the Products and the efforts in performing the Development Plan. These reports will cover, among other things: a summary of the work performed, a summary of the work in progress, the updated schedule of expected dates for completion of development stages and marketing authorizations, the status of the manufacture and the prospection for sublicenses, and the marketing plans for the launch of the Product. In the event of the termination of the Agreement, Licensee shall provide Inserm Transfert with a final report within thirty (30) days of the termination of the Agreement.
3.3 Licensee undertakes to inform Inserm Transfert of any identified event relating to the development.
3.4 Licensee agrees to undertake all commercially reasonable efforts to develop the Products as soon as possible, consistent with reasonable business practices and in compliance with the Development Plan.
3.5 Licensee agrees to undertake all commercially reasonable efforts to commercialize the Products as soon as possible, consistent with reasonable business practices and with the regulatory approvals necessary.
3.6 Inserm Transfert may terminate the Agreement ipso jure in whole or in part as regards the Patent Rights, in the event Licensee is unable to timely meet any of the Development Activities milestones as set forth in the Development Plan on the respective scheduled date and if License...
Development Commercialization. Mymetics commits to establish, and comply with, a specific schedule for the commercial development of this project and to inform the other Party of its progress; INSERM-TRANSFERT may terminate the Agreement if Mymetics does not make reasonable efforts to comply with the above-mentioned schedule or should Mymetics interrupt its development, exploitation or sales efforts during specific periods of time. Mymetics to commits to comply with all applicable laws and regulations while carrying out this project. Mymetics will bear all the costs for the required registrations and sale authorizations. Mymetics will periodically inform INSERM-TRANSFERT of the progress of the project and will send to INSERM-TRANSFERT an annual written report in this regard.
Development Commercialization. Other than those activities identified in a Research Plan as being Immatics Research Activities, Moderna shall have sole responsibility for, and control of, Developing, Manufacturing and Commercializing Products in the Field in the Territory.
Development Commercialization. Purchaser shall use its reasonable commercial diligence in developing and commercializing Migralex’s technologies. Subject to Seller’s rights pursuant to Section 8.06, Ember will invest at least five million dollars ($5,000,000) in sales and marketing and product line extension during the twelve (12) month period following the Closing.
Development Commercialization. Section 5.1 Development, Commercialization and Regulatory Responsibilities. OncoGenex will have sole responsibility, including without limitation sole responsibility for all funding, resourcing and decision making, for all further development and commercialization with respect to OGX-011 and Products. OncoGenex hereby assumes all regulatory responsibilities in connection with OGX-011 and Products, including sole responsibility for all Regulatory Documents and for obtaining all regulatory approvals. OncoGenex will comply with all Applicable Laws in connection with the development and commercialization of OGX-011 and Products. All INDs, NDAs, XXXx and other regulatory filings for OGX-011 and Products will be owned by OncoGenex.
Development Commercialization. The Development and Commercialization of any Product hereunder by Licensee shall be in Licensee’s sole discretion and expense; provided, however, that, in the course of such activities, Licensee shall have, and maintain at all times during the term of this Agreement, a governance policy that requires the Licensee to comply in all material aspects with applicable laws and regulations relating to the research, Development, and Commercialization of pharmaceutical products, as well as laws and regulations relating to health, safety, and the environment, fair labor practices, anti-corruption, and anti-bribery.
Development Commercialization
